COVID-19. COVID-19 confirmed by laboratory testing
Conditions
Interventions
Intervention 1: Intervention group: this group adjunct to standard treatment will receive intravenous infusion of 12 grams of vitamin C in Dextrose 5% serum to the total volume of 200 ml over 24 hour
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Older than 18 years old admission with moderate to severe COVID-19 based on WHO definition Illness of any duration, and at least one of the following: Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or Clinical assessment AND respiratory rate > 30 breaths/min; or severe respiratory distress; or SpO2 < 90% on room air. Willing and be able to provide written informed consent prior to performing study procedures
Exclusion criteria
Exclusion criteria: Participation in any other clinical trial of an experimental treatment for COVID-19 Critical ill patients that need invasive mechanical ventilation Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30) Patients with past medical history of kidney stone Pregnancy or breastfeeding Documented diagnosis of cancer? History of G6PD deficiency ?and interstitial lung disease ? More than 1 gram/day intake of vitamin C ?supplement in last 7 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to clinical improvement (TTIC). Timepoint: day 0, 5, at discharge. Method of measurement: assessing respiratory rate, blood oxygen saturation, fever.;Change in Sequential Organ Failure Assessment (SOFA) score. Timepoint: day 0, 3, and 5. Method of measurement: SOFA scoring system. | — |
Secondary
| Measure | Time frame |
|---|---|
| National Early Warning Score (NEWS) 2. Timepoint: On day 0, 3, and 5. Method of measurement: NEWS 2 scoring system.;Ordinal scale for clinical improvement. Timepoint: On day 0, 3, and 5. Method of measurement: WHO scoring system.;Hospital Length of Stay. Timepoint: Days after receiving infusion. Method of measurement: days.;The change of inflammatory markers. Timepoint: On day 0, 3, and 5. Method of measurement: C-reactive protein, Neutrophil-lymphocyte ratio, Ferritin.;Mortality. Timepoint: During 30 days of receiving infusion. Method of measurement: Number of subjects. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKourosh Sadeghi
Tehran University of Medical Sciences
Outcome results
None listed